Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jan 8, 2022
Finance
Buysiders eye 2022 as the year of immuno-oncology’s next big act
High hopes for catalysts brewing for years have investors expecting a new era, and neurology may be on the upswing too
BioCentury | Aug 21, 2021
Targets & Mechanisms
Next-generation multiple sclerosis therapies look beyond B cells
Early-stage approaches aim for more precise immune suppression, remyelination
BioCentury | Apr 15, 2020
Emerging Company Profile
Backed by Third Rock-led syndicate, MOMA seeks new ATP-powered targets by interrogating 'molecular machines'
MOMA plans to take a systematic approach to surveying a class of enzymes involved in cellular processes
BioCentury | Dec 12, 2019
Company News
Dec. 11 Company Quick Takes: Kite, Alkermes, argenx, Reblozyl, Denovo-Sunesis
BioCentury | Aug 2, 2019
Distillery Therapeutics
Small molecules that prevent stress granule formation in ALS
BioCentury | Mar 29, 2019
Targets & Mechanisms
Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment
A look at new and emerging targets at AACR 2019 and their mechanisms
BioCentury | Sep 1, 2017
Company News
CellAct grants Mundiphamra to develop and commercialie rights to CAP7.1
Items per page:
1 - 10 of 231